Today, CG Oncology announced that Arthur Kuan, @KuanArthur , Chairman & Chief Executive Officer, and Ambaw Bellete, @abellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California. To learn more, please read our release: bit.ly/4q9SDpK

The team at CG Oncology is looking forward to returning to this year’s @UroOnc #SUO2025 early next month. We are proud to have two late-breaking abstracts selected for the conference: topline results from Cohort P of our BOND-003 trial and first results from Cohort A of our CORE-008 trial, both evaluating our lead candidate cretostimogene grenadenorepvec in non-muscle invasive bladder cancer patients. See our press release here for more information on our late-breakers and our posters at SUO: bit.ly/4rjQo3R See you in Phoenix, Dec. 2-5! #SUO #Urology #BladderCancer #Oncology #CGOncology

Last week our team was honored to participate in the annual BCAN Bladder Cancer Think Tank Meeting in Washington D.C. Thank you to #BCAN for convening such an important and impactful forum.

In updated Phase 3 BOND-003 data shared at #SUO2024, cretostimogene grenadenorepvec showed sustained, durable complete responses in high-risk BCG-unresponsive #NMIBC. See how CG Oncology is advancing innovation in the fight against #bladdercancer.

We're thrilled to present our latest data today! Join us to hear from @SvatekRob, MD & @MarkTysonMD as they present on their respective ongoing trials: PIVOT-006 at 10:24 am and BOND-003 at 10:56 am CDT in the Learning Lab. Come join us! 👉Full agenda: auanet.org/AUA2024

It was a full house at the #AUA2024 "Clinical Trials in Progress, Bladder Cancer" session, featuring presentations by @SvatekRob on the PIVOT-006 study & @MarkTysonMD on the BOND-003- Cohort P. Learn more and discover our latest advances in #bladdercancer at booth #100! 🤝